Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib 72-Hour Continuous IV Infusion in MDS and AML
NCT00854945Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Jan 2009
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rigosertib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Traws Pharma, Inc.. Started Jan 2009; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00854945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00854945.